Back to results
US 7,740,850 B2Granted
PDGFRβ-specific antibodies
AssigneeImClone LLC
InventorsZhenping Zhu, Juqun Shen
Life of this patent
Estimating the term…
Abstract
The invention is directed to novel PDGFRβ-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFRβ-specific antagonists with VEGFR antagonists for such treatments. The antagonists can further be administered in combination with other anti-angiogenic or anti-neoplastic drugs.
Claims6
An antibody or fragment thereof that binds human PDGFRβ, comprising SYAIS (SEQ ID NO:20) at CDRH1;
- RIIPILGIANYAQKFQG (SEQ ID NO:22) at CDRH2;
- DMGSRNYYYFY (SEQ ID NO:24) at CDRH3;
- RASQSVGRYLA (SEQ ID NO:28) at CDRL1;
- GASNRAT (SEQ ID NO:30) at CDRL2;
- and QQRSNWPLT (SEQ ID NO:32) at CDRL3.
2 more elements
Dependencies are inferred from the claim text.